var data={"title":"Recombinant human growth hormone (somatropin): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Recombinant human growth hormone (somatropin): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6977?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-drug-information\" class=\"drug drug_general\">see &quot;Recombinant human growth hormone (somatropin): Drug information&quot;</a> and <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Recombinant human growth hormone (somatropin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222357\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Genotropin;</li>\n      <li>Genotropin MiniQuick;</li>\n      <li>Humatrope;</li>\n      <li>Norditropin FlexPro;</li>\n      <li>Norditropin NordiFlex Pen [DSC];</li>\n      <li>Nutropin AQ NuSpin 10;</li>\n      <li>Nutropin AQ NuSpin 20;</li>\n      <li>Nutropin AQ NuSpin 5;</li>\n      <li>Nutropin AQ Pen [DSC];</li>\n      <li>Omnitrope;</li>\n      <li>Saizen;</li>\n      <li>Saizen Click.Easy;</li>\n      <li>Saizenprep;</li>\n      <li>Serostim;</li>\n      <li>Tev-Tropin [DSC];</li>\n      <li>Zomacton;</li>\n      <li>Zorbtive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222358\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Genotropin GoQuick;</li>\n      <li>Genotropin MiniQuick;</li>\n      <li>Humatrope;</li>\n      <li>Norditropin Nordiflex;</li>\n      <li>Norditropin Simplexx;</li>\n      <li>Nutropin AQ NuSpin;</li>\n      <li>Nutropin AQ Pen;</li>\n      <li>Omnitrope;</li>\n      <li>Saizen;</li>\n      <li>Serostim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062319\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Growth Hormone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062312\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-drug-information\" class=\"drug drug_general\">see &quot;Recombinant human growth hormone (somatropin): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Nutropin (lyophilized powder) has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>AIDS-related wasting or cachexia:</b> Serostim&reg;: Children &ge;6 years and Adolescents:  Limited data available: SubQ: 0.04-0.07 mg/kg/day for 4 weeks; dosing based on two small trials of pediatric patients (n=11; age: 6-17 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chronic renal insufficiency:</b> Nutropin&reg;, Nutropin&reg; AQ: SubQ: 0.35 mg/kg <b>weekly</b> divided into daily injections; continue until the time of renal transplantation </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dosage recommendations in patients treated for CRI who require dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: Administer dose at night prior to bedtime or at least 3-4 hours after hemodialysis to prevent hematoma formation from heparin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CCPD: Administer dose in the morning following dialysis </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CAPD: Administer dose in the evening at the time of overnight exchange</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Growth hormone inadequacy: Note: </b>Therapy should be discontinued when patient has reached satisfactory adult height, when epiphyses have fused, or when the patient ceases to respond. Growth of 5 cm/year or more is expected; if growth rate does not exceed 2.5 cm in a 6-month period, double the dose for the next 6 months; if there is still no satisfactory response, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Genotropin&reg;, Omnitrope&reg;: SubQ: 0.16-0.24 mg/kg <b>weekly</b> divided into daily doses (6-7 doses) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Humatrope&reg;: SubQ: 0.18-0.3 mg/kg <b>weekly</b> divided into equal doses 6-7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Norditropin&reg;: SubQ: 0.024-0.034 mg/kg/dose 6-7 times per week </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nutropin&reg;, Nutropin&reg; AQ: SubQ: 0.3 mg/kg <b>weekly</b> divided into daily doses; in pubertal patients, dosage may be increased to 0.7 mg/kg <b>weekly</b> divided into daily doses </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Saizen&reg;: IM, SubQ: 0.18 mg/kg <b>weekly</b> divided into equal daily doses <b>or</b> as 0.06 mg/kg/dose administered 3 days per week <b>or</b> as 0.03 mg/kg/dose administered 6 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tev-Tropin&trade;: SubQ: 0.3 mg/kg divided 3 times per week </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Idiopathic short stature:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Genotropin&reg;, Omnitrope&reg;: SubQ: 0.47 mg/kg <b>weekly</b> divided into equal doses 6-7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Humatrope&reg;: SubQ: 0.37 mg/kg <b>weekly</b> divided into daily doses (6-7 doses)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nutropin&reg;, Nutropin&reg; AQ: SubQ: Up to 0.3 mg/kg <b>weekly</b> divided into daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Noonan syndrome:</b> Norditropin&reg;: SubQ: Up to 0.066 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prader-Willi syndrome:</b> Genotropin&reg;, Omnitrope&reg;: SubQ: 0.24 mg/kg <b>weekly</b> divided daily into 6-7 doses per week </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>SGA at birth who fail to catch-up by 2-4 years of age:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Genotropin&reg;, Omnitrope: 0.48 mg/kg <b>weekly</b> divided daily into 6-7 doses per week </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Humatrope&reg;: SubQ: 0.47 mg/kg <b>weekly</b>divided into equal doses 6-7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Norditropin&reg;: SubQ: Up to 0.469 mg/kg <b>weekly</b> divided into equal doses 7 days/week </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Alternate dosing (small for gestational age):</i> In older/early pubertal children or children with very short stature, consider initiating therapy at higher doses (0.469 mg/kg weekly divided into equal doses 7 days/week); then consider reducing the dose (0.231 mg/kg weekly) if substantial catch-up growth observed. In younger children (&lt;4 years) with less severe short stature, consider initiating therapy with lower doses (0.231 mg/kg weekly) and then titrating the dose upwards as needed. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>SHOX deficiency:</b> Humatrope&reg;: SubQ: 0.35 mg/kg <b>weekly</b> divided into equal doses 6-7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Turner syndrome:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Genotropin&reg;; Omnitrope&reg;: SubQ: 0.33 mg/kg <b>weekly</b> divided into 6-7 doses/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Humatrope&reg;: SubQ: 0.375 mg/kg <b>weekly</b> divided into equal doses 6-7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nutropin&reg;, Nutropin&reg; AQ: SubQ: Up to 0.375 mg/kg <b>weekly</b> divided into equal doses 3-7 times/week </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>AIDS-related wasting or cachexia:</b> Serostim&reg;: SubQ: Administered once daily at bedtime:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;35 kg: 0.1 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">35-44 kg: 4 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">45-55 kg: 5 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;55 kg: 6 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Growth hormone deficiency: Note:</b> To minimize adverse events in older or overweight patients, reduced dosages may be necessary. During therapy, dosage should be decreased if required by the occurrence of side effects or excessive IGF-1 levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Weight-based dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Norditropin&reg;: SubQ: Initial dose &le;0.028 mg/kg <b>weekly</b> divided into equal doses 7 days/week; after 6 weeks of therapy, may increase dose to 0.112 mg/kg weekly divided into equal doses 7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Nutropin&reg;, Nutropin&reg; AQ: SubQ: &le;0.006 mg/kg/day; dose may be increased according to individual requirements, up to a maximum of 0.025 mg/kg/day in patients &lt;35 years of age, or up to a maximum of 0.0125 mg/kg/day in patients &ge;35 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Humatrope&reg;: SubQ: &le;0.006 mg/kg/day; dose may be increased according to individual requirements, up to a maximum of 0.0125 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Genotropin&reg;, Omnitrope&reg;: SubQ: &le;0.04 mg/kg <b>weekly</b> divided into 6-7 doses; dose may be increased at 4- to 8-week intervals according to individual requirements, to a maximum of 0.08 mg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Saizen&reg;: SubQ: &le;0.005 mg/kg/day; dose may be increased to not more than 0.01 mg/kg/day after 4 weeks, based on individual requirements</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Nonweight-based dosing:</i> SubQ: Initial: 0.2 mg/day (range: 0.15-0.3 mg/day); may increase every 1-2 months by 0.1-0.2 mg/day based on response and/or serum IGF-I levels </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosage adjustment with estrogen supplementation (growth hormone deficiency):</i> Larger doses of somatropin may be needed for women taking oral estrogen replacement products; dosing not affected by topical products</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Short-bowel syndrome:</b> Zorbtive&reg;: SubQ: 0.1 mg/kg daily not to exceed 8 mg/day; treatment &gt;4 weeks has not been studied adequately. Excessive fluid retention or arthralgias may be treated symptomatically or by a 50% dosage reduction; stop therapy for up to 5 days prior to lowering dosage if symptoms are severe; if symptoms do not resolve after 5 days or recur with the lowered dosage, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> Reports indicate patients with chronic renal failure tend to have decreased clearance; specific dosing suggestions not available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Clearance may be reduced in patients with severe hepatic dysfunction; specific dosing suggestions not available</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222338\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norditropin FlexPro: 5 mg/1.5 mL (1.5 mL); 10 mg/1.5 mL (1.5 mL); 15 mg/1.5 mL (1.5 mL); 30 mg/3 mL (3 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norditropin NordiFlex Pen: 30 mg/3 mL (3 mL [DSC]) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 5: 5 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 10: 10 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 20: 20 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ Pen: 10 mg/2 mL (2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ Pen: 20 mg/2 mL (2 mL [DSC]) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 5 mg/1.5 mL (1.5 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 10 mg/1.5 mL (1.5 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humatrope: 5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humatrope: 6 mg (1 ea); 12 mg (1 ea); 24 mg (1 ea) [contains glycerin, metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizen: 5 mg (1 ea); 8.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizen Click.Easy: 8.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizenprep: 8.8 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genotropin: 5 mg (1 ea); 12 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 5.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serostim: 4 mg (1 ea); 5 mg (1 ea); 6 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tev-Tropin: 5 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zomacton: 5 mg (1 ea) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zomacton: 10 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zorbtive: 8.8 mg (1 ea) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genotropin MiniQuick: 0.2 mg (1 ea); 0.4 mg (1 ea); 0.6 mg (1 ea); 0.8 mg (1 ea); 1 mg (1 ea); 1.2 mg (1 ea); 1.4 mg (1 ea); 1.6 mg (1 ea); 1.8 mg (1 ea); 2 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222323\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27662100\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Nutropin (lyophilized powder) has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062322\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Parenteral: Administer SubQ notfor IV injection; do not shake vial. Administer into the thigh, buttock, or abdomen; rotate administration sites to avoid tissue atrophy. <b>Note:</b> Some products previously approved for IM administration; however, this route has been replaced with SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Product-specific information: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Norditropin cartridge must be administered using the corresponding color-coded NordiPen injection pen; do not interchange. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omnitrope: Solution in the Omnitrope cartridges must be administered using the Omnitrope pen; when installing a new cartridge, prime pen prior to first use. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tev-Tropin: When administering Tev-Tropin, use a standard sterile disposable needle or Tjet \tNeedle-Free injection device for SubQ injection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of administration for chronic renal insufficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis (HD): Administer at night just prior to sleeping and at least 3 to 4 hours after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic cycling: Administer in the morning after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer in the evening at the time of the overnight exchange</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222353\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genotropin:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cartridge: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Following reconstitution, may store under refrigeration for up to 28 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miniquick: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) prior to dispensing; may be stored &le;25&deg;C (77&deg;F) for up to 3 months after dispensing. Store in original carton to protect from light; do not freeze. Once reconstituted, solution must be refrigerated and used within 24 hours. Discard unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Humatrope:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cartridge: Before and after reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Following reconstitution with provided diluent, stable for 28 days under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vial: Before and after reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. When reconstituted with provided diluent or bacteriostatic water for injection (benzyl alcohol preserved), use within 14 days. When reconstituted with sterile water for injection, use within 24 hours and discard unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norditropin: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Avoid direct light. Pens in use may be stored in refrigerator and used within 4 weeks after initial injection or may be stored up to 3 weeks at &le;25&deg;C (77&deg;F). Discard unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nutropin: Before and after reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Use vials reconstituted with bacteriostatic water for injection (benzyl alcohol preserved) within 14 days; when reconstituted with sterile water for injection, use immediately and discard unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nutropin AQ: Before and after reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Use within 28 days following initial use. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omnitrope:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cartridge: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Once the cartridge is loaded into the pen delivery system, store under refrigeration for up to 28 days after first use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vial: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Following reconstitution, store under refrigeration for up to 3 weeks. Store vial in carton to protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saizen:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cartridge: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution with the provided diluent, store under refrigeration for up to 21 days. Avoid freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vial: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution with bacteriostatic water for injection (benzyl alcohol preserved), store under refrigeration for up to 14 days. Following reconstitution with sterile water for injection, use immediately and discard unused portion. Avoid freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serostim: Prior to reconstitution, store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution with sterile water for injection, use immediately and discard unused portion. Following reconstitution with bacteriostatic water for injection (benzyl alcohol preserved), store under refrigeration for up to 14 days; avoid freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tev-Tropin, Zomacton: Prior to reconstitution, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Following reconstitution with the provided diluent, store under refrigeration and use within 14 days (5 mg vial) or 28 days (10 mg vial); do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zorbtive: Store intact vials and diluent at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution with the provided diluent (bacteriostatic water for injection containing benzyl alcohol), may store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 14 days; do not freeze. If reconstituted with sterile water for injection, solution should be used immediately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062321\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of growth failure due to inadequate endogenous growth hormone secretion (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;, Saizen&reg;, Tev-Tropin&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of short stature associated with Turner syndrome (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of Prader-Willi syndrome (Genotropin&reg;, Omnitrope&reg;: FDA approved in ages &gt; 2 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of growth failure associated with chronic renal insufficiency (CRI) up until the time of renal transplantation (Nutropin&reg;, Nutropin AQ&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by 2-4 years of age (Genotropin&reg;, Humatrope&reg;, Norditropin&reg; Omnitrope&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of idiopathic short stature (nongrowth hormone-deficient short stature) defined by height standard deviation score (SDS) &le;2.25 and growth rate not likely to attain normal adult height (Genotropin&reg;, Humatrope&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of short stature or growth failure associated with short stature homeobox gene (SHOX) deficiency (Humatrope&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of short stature associated with Noonan syndrome (Norditropin&reg;: FDA approved in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: All indications: FDA approved in adults </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HIV patients with wasting or cachexia with concomitant antiviral therapy (Serostim&reg;)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Replacement of endogenous growth hormone in patients with adult growth hormone deficiency who meet both of the following criteria (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;, Saizen&reg;):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Biochemical diagnosis of adult growth hormone deficiency by means of a subnormal response to a standard growth hormone stimulation test (peak growth hormone &le;5 mcg/L). Confirmatory testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>and</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adult-onset: Patients who have adult growth hormone deficiency whether alone or with multiple hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Childhood-onset: Patients who were growth hormone-deficient during childhood, confirmed as an adult before replacement therapy is initiated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of short-bowel syndrome (Zorbtive&reg;)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222386\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Humatrope may be confused with homatropine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Somatrem may be confused with somatropin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Somatropin may be confused with homatropine, sumatriptan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Growth hormone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older except as hormone replacement following pituitary gland removal due to its minimal impact on body composition and its association with causing edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222383\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain (adults), edema (more common in adults), facial edema, hypertension, lower extremity edema (adults), peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior (children), carpal tunnel syndrome, depression (adults), fatigue, headache (more common in adults), hypoesthesia, insomnia (adults), nipple pain, pain, paresthesia, seizure (children), sleep apnea (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (children), diaphoresis, exacerbation of psoriasis (children), nevus (including progression and melanocytic), rash at injection site (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dependent edema (adults), diabetes mellitus (includes exacerbation and new-onset), disturbance in fluid balance (children), elevated glycosylated hemoglobin (children), eosinophilia (children), fluid retention, glycosuria (adults), gynecomastia, hyperglycemia, hyperlipidemia (children), hypertriglyceridemia, hypoglycemia (children), hypothyroidism (more common in children), impaired glucose tolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, flatulence, gastroenteritis (children), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast hypertrophy, breast neoplasm, breast swelling, breast tenderness, hematuria (children), mastalgia, urinary tract infection (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hematoma (children), meningioma (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (adults), influenza (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Bleeding at injection site (children), burning sensation at injection site (children), erythema at injection site (children), fibrosis at injection site (children), inflammation at injection site (children), injection site nodule (children), injection site numbness (children), injection site reaction, local skin hyperpigmentation (children; injection site), pain at injection site, swelling at injection site (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Abnormal bone growth (children; including disproportional growth of lower jaw), arthralgia, arthropathy (more common in adults), hip pain (children), joint stiffness, joint swelling, leg pain (children), limb pain, lipoatrophy (children), musculoskeletal disease (discomfort), myalgia, ostealgia (adults), scoliosis (children; exacerbation or new), stiffness (adults; includes extremities and musculoskeletal), swelling of extremities, tonsillitis (children), weakness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Periorbital edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis (children), otitis media (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, dyspnea (adults), flu-like symptoms, pharyngitis (children), sinusitis (children), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, arthritis, avascular necrosis of femoral head (Legg-Calve-Perthes disease), bone fracture, cardiac disease, CNS neoplasm (children), diabetic coma, diabetic ketoacidosis, diabetic retinopathy, hypersensitivity reaction, illness (acute critical), intracranial hypertension (includes benign intracranial hypertension in children), leukemia, malignant neoplasm (includes new or recurrence or intracranial tumor), neoplasm (children; benign, new or recurring), nerve compression, pancreatitis, papilledema, precocious puberty, slipped capital femoral epiphysis, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222343\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to somatropin or any component of the formulation; growth promotion in pediatric patients with closed epiphyses; acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; active malignancy; active proliferative or severe nonproliferative diabetic retinopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional product-specific contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with Prader-Willi syndrome who have a history of upper airway obstruction or sleep apnea (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Zomacton)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222327\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Fluid retention may occur in adults; manifestations of fluid retention (eg, edema, arthralgia, myalgia, nerve compression syndromes [including carpal tunnel syndrome]/paresthesias) are generally transient and dose dependent. If symptoms of carpal tunnel syndrome do not resolve by decreasing the dose or frequency of somatropin, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose tolerance: Somatropin may decrease insulin sensitivity. Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be detected; new-onset type 2 diabetes mellitus, and exacerbation of preexisting diabetes mellitus may occur. Diabetic ketoacidosis and diabetic coma have been reported in some patients. Discontinuing somatropin may improve glucose tolerance in some patients. Adjustment of antidiabetic medications may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Intracranial hypertension with headache, nausea, papilledema, visual changes, and/or vomiting has been reported; symptoms usually occur within the first 8 weeks of therapy and signs and symptoms of intracranial hypertension may rapidly resolve after discontinuation or reduction of dose. Funduscopic examination prior to initiation of therapy and periodically thereafter is recommended. Treatment should be discontinued in patients who develop papilledema; resuming treatment at a lower dose may be considered once IH-associated signs and symptoms have resolved. Patients with Turner syndrome, chronic renal impairment and Prader-Willi syndrome may be at increased risk for intracranial hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipoatrophy: Lipoatrophy has been reported at injection sites when used at the same site for a prolonged period. Ensure proper injection technique and rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neoplasm: Any preexisting malignancy should be inactive and treatment complete prior to initiating therapy; discontinue therapy with evidence of recurrence or progression. Monitor patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion for recurrence or progression of underlying disease. An increased risk of second neoplasm has been reported in childhood cancer survivors treated with somatropin; the most common second neoplasms were meningiomas in patients treated with radiation to the head for their first neoplasm. Patients with HIV and pediatric patients with short stature (genetic cause) have increased baseline risk of developing malignancies; consider risk/benefits prior to initiation of therapy and monitor these patients carefully. Monitor all patients for any malignant transformation of skin lesions. Rule out pituitary tumor (or other brain tumors) prior to initiation of treatment because growth hormone deficiency may be an early sign of the presence of these tumors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has been rarely reported; incidence in children (especially girls) with Turner syndrome may be greater than adults. Consider pancreatitis diagnosis if abdominal pain occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slipped capital femoral epiphyses: Patients with endocrine disorders (including growth hormone deficiency and Turner syndrome) or in patients undergoing rapid growth may develop slipped capital femoral epiphyses more frequently; evaluate any child with new onset of a limp or with complaints of hip or knee pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute critical illness: Initiation of somatropin is contraindicated with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; mortality may be increased. Discontinuation of therapy may be necessary in patients with an acute critical illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Childhood-onset adult growth hormone deficiency: Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin for growth hormone deficiency in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease: Periodically monitor children with growth failure secondary to chronic kidney disease (CKD) for evidence of progression of renal osteodystrophy. Slipped capital femoral epiphysis or avascular necrosis of the femoral head may be seen in children with advanced renal osteodystrophy. Obtain x-rays of the hip prior to initiating somatropin in CKD patients; be alert to the development of a limp or complaints of hip or knee pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoadrenalism: Patients who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism with somatropin therapy; patients with previously diagnosed hypoadrenalism may require increased dosages of glucocorticoids due to the effects of somatropin. Excessive glucocorticoid therapy may inhibit the growth-promoting effects of somatropin in children; monitor and adjust glucocorticoids carefully.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Patients who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced thyroid function (central hypothyroidism). Untreated/undiagnosed hypothyroidism may decrease response to therapy, particularly the growth response in children. Monitor thyroid function periodically and initiate/adjust thyroid replacement therapy as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Noonan syndrome: Safety has not been established for the treatment of Noonan syndrome in children with significant cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prader-Willi syndrome: Fatalities have been reported in pediatric patients with Prader-Willi syndrome following the use of growth hormone. The reported fatalities occurred in patients with one or more risk factors, including severe obesity, history of upper airway obstruction or sleep apnea, respiratory impairment, or unidentified respiratory infection; male patients may be at greater risk. Monitor for sleep apnea, upper airway obstruction, and respiratory infections prior to initiation of therapy and periodically thereafter. Treatment interruption is recommended in patients who show signs of upper airway obstruction, including the onset of, or increased, snoring and/or new-onset sleep apnea. All patients with Prader-Willi syndrome should have effective weight control. Unless patients with Prader-Willi syndrome <b>also</b> have a diagnosis of growth hormone deficiency, use is not indicated for the long-term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Scoliosis: Progression of scoliosis may occur in children experiencing rapid growth; monitor for worsening of scoliosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Turner syndrome: Patients with Turner syndrome are at increased risk for otitis media and other ear/hearing disorders, autoimmune thyroid disease, primary hypothyroidism, and cardiovascular disorders (eg, hypertension, aortic aneurysm/dissection, stroke). Monitor patients with Turner syndrome for these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients may be more sensitive to the actions of somatropin; consider lower starting doses and smaller dose increments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV patients: Patients with HIV infection should be maintained on antiretroviral therapy to prevent the potential increase in viral replication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Failure to increase growth rate, particularly during the first year of therapy, indicates need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age, and antibodies to recombinant human GH.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal transplant recipients: No studies have been completed evaluating Nutropin or Nutropin AQ in patients with renal transplant. Use is not indicated in patients with functioning renal allografts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; M-cresol: Some products may contain m-cresol as a preservative.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300073\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222332\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13354&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cortisone: Somatropin may diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women. Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).<b> Exceptions: </b>Ethinyl Estradiol; Mestranol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Growth Hormone Products may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: Somatropin may diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Somatropin may diminish the therapeutic effect of Thyroid Products. <b> Exceptions: </b>Liothyronine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222334\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (depending upon manufacturer) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3984740\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies, however, reproduction studies have not been conducted with all agents. During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Data with somatropin use during pregnancy is limited (Vila 2015; Yoshizawa 2017) and recommendations related to use in pregnant women cannot be made (AACE [Cook 2009]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062318\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth curve, periodic thyroid function tests, bone age (annually), periodical urine testing for glucose, somatomedin C levels; fundoscopic exams; progression of scoliosis and clinical evidence of slipped capital femoral epiphysis such as a limp or hip or knee pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222326\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Somatropin is a purified polypeptide hormones of recombinant DNA origin; somatropin contains the identical sequence of amino acids found in human growth hormone; human growth hormone assists growth of linear bone, skeletal muscle, and organs by stimulating chondrocyte proliferation and differentiation, lipolysis, protein synthesis, and hepatic glucose output; stimulates erythropoietin which increases red blood cell mass; exerts both insulin-like and diabetogenic effects; enhances the transmucosal transport of water, electrolytes, and nutrients across the gut</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222342\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Nutropin AQ: 50 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: Nutropin AQ; Saizen; Serostim; Zorbtive: 70% to 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotropin: SubQ: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humatrope: SubQ: 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Norditropin: SubQ: ~7 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nutropin, Nutropin AQ: SubQ: 2.1 &plusmn; 0.43 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omnitrope: SubQ: 2.5 to 2.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Saizen: SubQ: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serostim: SubQ: 4.28 &plusmn; 2.15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zomacton: SubQ: <b>~</b>2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zorbtive: SubQ: 4 &plusmn; 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222345\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Norditropin FlexPro Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/1.5 mL (1.5 mL): $706.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/1.5 mL (1.5 mL): $1,413.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/1.5 mL (1.5 mL): $2,120.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/3 mL (3 mL): $4,240.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 10 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $1,508.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 20 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $3,017.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 5 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/2 mL (2 mL): $754.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Omnitrope Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/1.5 mL (1.5 mL): $714.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/1.5 mL (1.5 mL): $1,429.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Genotropin MiniQuick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (1): $31.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (1): $63.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (1): $95.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg (1): $127.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $158.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 mg (1): $190.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.4 mg (1): $222.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.6 mg (1): $254.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.8 mg (1): $285.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $317.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Genotropin Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $728.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (1): $1,747.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Humatrope Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $736.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (1): $883.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (1): $1,766.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg (1): $3,533.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Omnitrope Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5.8 mg (1): $367.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizen Click.Easy Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $709.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizenprep Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Serostim Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $396.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $496.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (1): $595.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zomacton Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $348.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $696.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zorbtive Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,462.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222347\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Caretropin (PH);</li>\n      <li>Declage (KR);</li>\n      <li>Eutropin (BR, IN, KR, TH);</li>\n      <li>Genheal (PH, TH);</li>\n      <li>Genotonorm (BE, ES, FR, LU);</li>\n      <li>Genotonorm Miniquick (FR);</li>\n      <li>Genotropin (AE, AR, AT, AU, BB, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, FI, GB, GR, GT, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LY, MT, MX, NI, NL, NO, NZ, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SV, SY, TH, TR, UY, VE, YE);</li>\n      <li>Genotropin Miniquick (BB);</li>\n      <li>Growject BC (JP);</li>\n      <li>Growtropin II (VN);</li>\n      <li>Growtropin-Aq (CO);</li>\n      <li>Growtropin-II (KR);</li>\n      <li>Henotropin (UA);</li>\n      <li>HHT (EC);</li>\n      <li>Humatrope (AR, AT, AU, BF, BJ, BR, CI, CL, ES, ET, GB, GH, GM, GN, KE, LK, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, PE, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nordilet (JO, KR);</li>\n      <li>Norditropin (AE, AR, AT, BB, BE, BG, BH, BR, CL, CN, CO, CZ, DK, EG, FI, GB, GR, HR, HU, ID, IE, IT, JO, JP, KR, KW, LB, LU, MT, MY, NL, NO, PT, QA, RO, RU, SA, SE, TW, UA, VN);</li>\n      <li>Norditropin Nordilet (SG, TH);</li>\n      <li>Norditropin S (JP);</li>\n      <li>Norditropin Simplex (KR);</li>\n      <li>Norditropin Simplexx (DE, ES, IS, LT, SI, SK);</li>\n      <li>Novell-Eutropin (ID);</li>\n      <li>Nutropin AQ (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Nutropinaq (FR);</li>\n      <li>Omnitrop (UA);</li>\n      <li>Omnitrope (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TR);</li>\n      <li>Saizen (AE, AR, AT, AU, BB, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DO, EC, EE, ES, FI, FR, GR, GT, HK, HN, HU, ID, IE, IL, IS, IT, JO, KR, KW, LB, MY, NI, NO, NZ, PA, PH, PT, QA, SA, SE, SG, SK, SV, TH, TR, TW, VN);</li>\n      <li>Sayzen (UA);</li>\n      <li>Scitropin (PH);</li>\n      <li>Scitropin A (AU, TH);</li>\n      <li>Scitropina (SG);</li>\n      <li>Somatonorm (HR);</li>\n      <li>Valtropin (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Xerendig (MX);</li>\n      <li>Zoamcton (PE);</li>\n      <li>Zomacton (AR, AT, AU, BE, BG, CZ, DK, EE, FI, GR, HK, KR, LT, NL, NO, RO, SE, SG, SK, VN);</li>\n      <li>Zomakton (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen P, Rogol AD, Deal CL, et al, &quot;Consensus Statement on the Diagnosis and Treatment of Children With Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop,&quot; <i>J Clin Endocrinol Metab</i>, 2008, 93(11):4210-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/18782877/pubmed\" target=\"_blank\" id=\"18782877\">18782877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gharib H, Cook DM, Saenger PH, et al, &quot;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children - 2003 Update,&quot; <i>Endocr Pract</i>, 2003, 9(1):64-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/12917095/pubmed\" target=\"_blank\" id=\"12917095\">12917095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howrie DL, &ldquo;Growth Hormone for the Treatment of Growth Failure in Children,&rdquo; <i>Clin Pharm</i>, 1987, 6(4):283-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/3311576 /pubmed\" target=\"_blank\" id=\"3311576 \">3311576 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molitch ME, Clemmons DR, Malozowski S, et al, &quot;Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline,&quot; <i>J Clin Endocrinol Metab</i>, 2006, 91(5):1621-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-pediatric-drug-information/abstract-text/16636129/pubmed\" target=\"_blank\" id=\"16636129\">16636129</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13354 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222357\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222358\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062319\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062312\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222338\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F222323\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F27662100\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062322\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F222353\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062321\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222386\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222383\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222343\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222327\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300073\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222332\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222334\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3984740\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062318\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222326\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F222342\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222345\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F222347\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13354|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-drug-information\" class=\"drug drug_general\">Recombinant human growth hormone (somatropin): Drug information</a></li><li><a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-patient-drug-information\" class=\"drug drug_patient\">Recombinant human growth hormone (somatropin): Patient drug information</a></li></ul></div></div>","javascript":null}